This article is more than 5 years old. Information may no longer be current.

Ocata receives patents for retinal pigment epithelium transplant technology

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ocata Therapeutics has received three new U.S. patents that expand the scope of earlier patents for retinal pigment epithelium transplant technology, according to a company press release.

The expanded patent protection includes “all formats and formulations of RPE cells, including suspensions and sheets of cells, for use as therapeutic agents, and the use of these formulations for treating ophthalmic diseases such as dry age related macular degeneration and Stargardt’s macular degeneration,” according to the release.

The addition of these new patents brings the total number of Ocata’s patents to seven that “specifically protect retinal pigmented epithelial products derived from human embryonic stem cells as well as any other pluripotent stem cell source including induced pluripotent stem cell sources,” according to the release.

“For the first time a pluripotent stem cell derived therapy is about to enter a pivotal trial for Stargardt’s disease and phase 2 clinical trials for dry age-related macular degeneration, bringing the possibility of these long awaited therapies that much closer to reality,” Eddy Anglade, MD, chief medical officer of Ocata, said in the release.